Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pilulka Lekarny AS's Other Operating Expense for the
six
months ended in Dec. 2025 was Kč0 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was Kč1,304 Mil.
Pilulka Lekarny AS's quarterly Other Operating Expense
declined
from Jun. 2024 (Kč764 Mil) to Dec. 2024 (Kč540 Mil) and
declined
from Dec. 2024 (Kč540 Mil) to Dec. 2025 (Kč0 Mil).
Pilulka Lekarny AS's annual Other Operating Expense
declined
from Dec. 2023 (Kč315 Mil) to Dec. 2024 (Kč211 Mil) and
declined
from Dec. 2024 (Kč211 Mil) to Dec. 2025 (Kč48 Mil).
Pilulka Lekarny AS Other Operating Expense Related Terms
Pilulka Lekarny AS Other Operating Expense Historical Data
* Premium members only.
The historical data trend for Pilulka Lekarny AS's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was Kč1,304 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of Kč1,304 Mil mean?
Pilulka Lekarny AS (XPRA:PINK) has a Other Operating Expense of Kč1,304 Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on Pilulka Lekarny AS and its competitors.
Is Pilulka Lekarny AS's Other Operating Expense too high?
Pilulka Lekarny AS's current Other Operating Expense is Kč1,304 Mil. Overall, Pilulka Lekarny AS has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pilulka Lekarny AS's Other Operating Expense compare to competitors?
Pilulka Lekarny AS's Other Operating Expense of Kč1,304 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Healthcare Providers & Services company?
A good Other Operating Expense depends on the Healthcare Providers & Services industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Pilulka Lekarny AS and its competitors. Pilulka Lekarny AS's current Other Operating Expense is Kč1,304 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pilulka Lekarny AS stock overvalued right now?
Based on GuruFocus' analysis, Pilulka Lekarny AS (XPRA:PINK) is currently considered Fairly Valued. The stock's GF Value™ is Kč109.96, compared to a current price of Kč118.00 — trading 7.3% above its estimated fair value. The current Other Operating Expense is Kč1,304 Mil. Pilulka Lekarny AS's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Pilulka Lekarny AS (XPRA:PINK), the current Other Operating Expense is Kč1,304 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pilulka Lekarny AS (XPRA:PINK) Overvalued in 2026?
Based on GuruFocus' analysis, Pilulka Lekarny AS stock appears to be overvalued.
The current stock price of Kč118.00 is trading 7.3% above its estimated GF Value™ of Kč109.96.
GuruFocus considers Pilulka Lekarny AS to be Fairly Valued.
Key valuation signals for XPRA:PINK:
Other Operating Expense: Kč1,304 Mil
GF Value™: Kč109.96 vs. price of Kč118.00 (7.3% above fair value)
No single metric tells the full story. See the XPRA:PINK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pilulka Lekarny AS operates an online pharmaceutical store by distribution of medicinal products. The store offers over-the-counter-drugs, dietary supplements, baby foods, mother care products, cosmetics, other prescription drugs, sport nutritional products, diagnostic test kits, orthopaedic supplies, first aid kits, and other related products.
50GF Score
Get the complete analysis for XPRA:PINK
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPRA:PINK has been successfully added to your 
